World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
46247
World Ranking
11537
National Ranking
5916

Overview

Ryan J. Sullivan is affiliated with Harvard University in the United States. Their research primarily spans the field of Medicine, with significant focus on Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine, and Cancer Research.

The scientist's main topics of work include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Melanoma and MAPK Pathways
  • Immunotherapy and Immune Responses
  • Cutaneous Melanoma Detection and Management
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies

Ryan J. Sullivan has contributed to various peer-reviewed journals frequently. Their most common publication venues are:

  • Journal of Clinical Oncology
  • Regular and Young Investigator Award Abstracts
  • Journal for ImmunoTherapy of Cancer
  • Cancer Research
  • Annals of Oncology

Notable recent papers authored or co-authored by Ryan J. Sullivan include:

  • "Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma," 2021, New England Journal of Medicine
  • "Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer," 2021, Cell
  • "Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study," 2024, The Lancet
  • "Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque," 2020, Circulation
  • "Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy," 2020, Cell

Frequent collaborators working alongside Ryan J. Sullivan include:

  • Kerry L. Reynolds
  • Genevieve M. Boland
  • Leyre Zubiri
  • Donald P. Lawrence
  • Justine V. Cohen

Best Publications

  • Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

    Itay Tirosh;Benjamin Izar;Benjamin Izar;Sanjay M. Prakadan;Marc H. Wadsworth

  • Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

    Daniel Y. Wang;Joe Elie Salem;Joe Elie Salem;Justine V. Cohen;Sunandana Chandra

  • Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

    Moshe Sade-Feldman;Moshe Sade-Feldman;Keren Yizhak;Stacey L. Bjorgaard;Stacey L. Bjorgaard;John P. Ray

  • A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

    Livnat Jerby-Arnon;Parin Shah;Michael S. Cuoco;Christopher Rodman

  • MYOCARDITIS IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS

    Syed S. Mahmood;Michael G. Fradley;Justine V. Cohen;Anju Nohria

  • Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor

    Y Shing;J Folkman;R Sullivan;C Butterfield

  • EGFR Mutations and ALK Rearrangements Are Associated With Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

    Justin F. Gainor;Alice T. Shaw;Lecia V. Sequist;Xiujun Fu

  • BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma

    Dennie Tompers Frederick;Adriano Piris;Alexandria P. Cogdill;Zachary A. Cooper

  • Resistance to checkpoint blockade therapy through inactivation of antigen presentation.

    Moshe Sade-Feldman;Moshe Sade-Feldman;Yunxin J. Jiao;Yunxin J. Jiao;Jonathan H. Chen;Jonathan H. Chen;Michael S. Rooney

  • Transforming fusions of FGFR and TACC genes in human glioblastoma

    Devendra Singh;Joseph Minhow Chan;Pietro Zoppoli;Francesco Niola;Francesco Niola

  • Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

    Alexander M. Menzies;Alexander M. Menzies;D. B. Johnson;S. Ramanujam;V. G. Atkinson

  • Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

    Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino

  • Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

    Noam Auslander;Gao Zhang;Joo Sang Lee;Joo Sang Lee;Dennie T. Frederick

  • Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

    Paul Nathan;Jessica C. Hassel;Piotr Rutkowski;Jean-Francois Baurain

  • MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

    Nikhil Wagle;Nikhil Wagle;Eliezer M. Van Allen;Eliezer M. Van Allen;Daniel J. Treacy;Dennie T. Frederick

  • Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

    Douglas B. Johnson;Monica V. Estrada;Roberto Salgado;Violeta Sanchez

  • Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

    Douglas B. Johnson;Garrett M. Frampton;Matthew J. Rioth;Erik Yusko

  • Clusters of circulating tumor cells traverse capillary-sized vessels

    Sam H. Au;Brian D. Storey;John C. Moore;Qin Tang

  • Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.

    Alexander T. Faje;Ryan Sullivan;Donald Lawrence;Nicholas A. Tritos

  • Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

    I. Tirosh;B. Izar;D. Treacy;J. J. Trombetta

Frequent Co-Authors

Keith T. Flaherty
Keith T. Flaherty Harvard University
Dennie T. Frederick
Dennie T. Frederick Broad Institute
Douglas B. Johnson
Douglas B. Johnson Vanderbilt University Medical Center
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Georgina V. Long
Georgina V. Long University of Sydney
F. Stephen Hodi
F. Stephen Hodi Harvard University
Alexander M. Menzies
Alexander M. Menzies University of Sydney
Michael B. Atkins
Michael B. Atkins Georgetown University
Jennifer A. Wargo
Jennifer A. Wargo The University of Texas MD Anderson Cancer Center
Nir Hacohen
Nir Hacohen Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways in healthcare can help students start rewarding careers more quickly or with increased flexibility. For those interested in the administrative side of healthcare, best online medical billing and coding schools allow you to study from home and enter the workforce with in-demand skills, often with the support of financial aid.

If direct patient care is your goal, becoming a nurse might be right for you. You can save time and reduce admission barriers by considering nursing schools that don't require teas test, making the application process smoother and more accessible.

For those eager to advance into healthcare management, you may want to look into accelerated healthcare administration degree online programs. These condensed formats help professionals upskill quickly while balancing other responsibilities.

Registered nurses can also grow their skills by enrolling in bridge programs such as the rn to np track, which helps you progress from RN to Nurse Practitioner and expand your clinical scope. Each of these educational routes offers unique benefits for building a fulfilling career in the medical field.

Best Scientists Citing Ryan J. Sullivan

Trending Scientists

Recently Published Articles